By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

If you are wondering whether Novavax (Nasdaq: NVAX) is priced attractively or already reflects its story, you are not alone. The stock last closed at US$9.75, with returns of 21.7% over 7 days, 40.5% ...

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Shares rose 6.6% Monday on new partnership strategy outlined at J.P. Morgan conference. Sanofi deal and cost cuts drive ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Novavax Inc (NASDAQ:NVAX) shares are trading higher. Reports show a rise in respiratory illnesses across the United States.

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the ...